# Perspective Therapeutics, Inc.: Form 10-KT, filed May 1, 2023

- Company: [Perspective Therapeutics, Inc.](/companies/catx.md) (CIK 728387)
- Form: 10-KT
- Filed: 2023-05-01
- Accepted by EDGAR: May 1, 2023, 17:03 ET
- Period: 2022-12-31
- Accession: 0001437749-23-011946
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/728387/000143774923011946/isr20230214_10kt.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/728387/000143774923011946/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2022-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 6 months, 2022-07-01 to 2022-12-31 | $3.6m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Cost of revenue | 6 months, 2022-07-01 to 2022-12-31 | $2.7m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 6 months, 2022-07-01 to 2022-12-31 | $817.0k | us-gaap:GrossProfit |
| Research and development | 6 months, 2022-07-01 to 2022-12-31 | $1.3m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 6 months, 2022-07-01 to 2022-12-31 | −$7.9m | us-gaap:OperatingIncomeLoss |
| Income tax | 6 months, 2022-07-01 to 2022-12-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 6 months, 2022-07-01 to 2022-12-31 | −$7.3m | us-gaap:NetIncomeLoss |
| Basic EPS | 6 months, 2022-07-01 to 2022-12-31 | −$0.05 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 6 months, 2022-07-01 to 2022-12-31 | −$6.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2022-07-01 to 2022-12-31 | $151.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2022-12-31 | $21.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2022-12-31 | $53.2m | us-gaap:AssetsCurrent |
| Total assets | at 2022-12-31 | $58.1m | us-gaap:Assets |
| Current liabilities | at 2022-12-31 | $2.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2022-12-31 | $3.4m | us-gaap:Liabilities |
| Shareholders' equity | at 2022-12-31 | $54.6m | us-gaap:StockholdersEquity |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/728387/000143774923011946/isr20230214_10kt.htm

Filed May 1, 2023.
Source: SEC EDGAR, the filing index for accession 0001437749-23-011946. Last ingested by Listed: Nov 6, 2026, 11:33 ET. No prices; not investment advice.